Cencora (COR)
| Market Cap | 47.60B |
| Revenue (ttm) | 271.58B |
| Net Income (ttm) | 1.87B |
| Shares Out | 199.48M |
| EPS (ttm) | 9.19 |
| PE Ratio | 25.97 |
| Forward PE | 17.26 |
| Dividend | $2.04 (0.85%) |
| Ex-Dividend Date | Feb 8, 2024 |
| Volume | 862,455 |
| Open | 239.22 |
| Previous Close | 238.26 |
| Day's Range | 236.24 - 239.26 |
| 52-Week Range | 163.37 - 246.75 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 235.00 (-1.52%) |
| Earnings Date | May 1, 2024 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institu... [Read more]
Financial Performance
In 2023, Cencora's revenue was $262.17 billion, an increase of 9.89% compared to the previous year's $238.59 billion. Earnings were $1.75 billion, an increase of 2.74%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for COR stock is "Buy." The 12-month stock price forecast is $235.0, which is a decrease of -1.52% from the latest price.
News
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening...
Cencora Announces Leadership Succession Plan
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Ex...
Cencora says hit by cyber attack on its information systems
Cencora Inc said it has learned that data from its information systems had been exfiltrated, some of which may contain personal information, the drug distributor said in a filing on Tuesday.
Cencora's FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--With the increasing number of cell and gene therapy (CGT) products in clinical development, Cencora's FormularyDecisions launched a new resource designed to provide...
Walgreens Boots pockets $992 mln after cutting Cencora stake for third time
U.S. drugstore chain Walgreens Boots Alliance on Wednesday said it has cut its stake in pharmaceutical distributor Cencora for the third time in just over six months, pocketing about $992 million.
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of ap...
Cencora Closes $500 Million Senior Notes Offering
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “No...
Cencora Releases 2023 ESG Report
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report. The report and the related E...
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritt...
Cencora raises profit outlook due to robust demand for high-priced specialty drug
Drug distributor Cencora raised its annual profit outlook on Wednesday, betting on strong demand for costly specialty medicines that treat diseases such as cancer and rheumatoid arthritis.
Cencora Reports Fiscal 2024 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 ...
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the ope...
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
BOSTON , Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribut...
Walgreens sells shares of drug distributor Cencora
Drugstore chain Walgreens Boots Alliance Inc. WBA, -2.62% on Thursday said it had sold shares of drug distributor Cencora Inc. COR, +0.02% for approximately $424 million. Walgreens also entered into a...
Walgreens Boots Alliance Sells Shares of Cencora, Inc. for $674 Million of Initial Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company”) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) (“Cencora”) common stock pursuant to...
Judge trims US lawsuit accusing Cencora of fueling opioid epidemic
A federal judge on Monday pared back a U.S. government lawsuit accusing drug distributor Cencora , formerly called AmerisourceBergen, of fueling the nation's deadly opioid epidemic by failing to repor...
Cencora beats quarterly profit estimates on specialty drug demand
Drug distributor Cencora reported a fourth-quarter profit on Thursday that beat analysts' estimates as strong demand for costly specialty medicines helped offset a decline in COVID-related drug sales.
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue incr...
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thu...
AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care.
AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, e...
Walgreens Sells AmerisourceBergen Shares To Raise $1.85 Billion To Pay Down Debt And Accelerate Health Strategy
Walgreens Boots Alliance has sold shares of AmerisourceBergen for initial proceeds of $2.85 billion, which will be used to accelerate the drugstore giant's healthcare strategy.
Walgreens sells $1.85 bln of AmerisourceBergen shares, further cutting stake
Walgreens Boots Alliance has sold some AmerisourceBergen Corp's shares for proceeds of about $1.85 billion, the U.S. drugstore chain said on Thursday, further cutting its ownership in the drug distrib...